In an interview with PharmaShots, Jan van de Winkel, co-founder, President, and CEO at Genmab shared his views on the US FDA's Accelerated Approval of Tivdak (tisotumab vedotin-tftv) for the Treatment of Recurrent or Metastatic Cervical Cancer
Shots:
Genmab and Seagen have reported the US FDA's accelerated approval which is based on the P-II innovaTV 204 clinical trials evaluating tisotumab vedotin in…
